Metabolic Research

Ret3trutide

Triple receptor agonist (GIP/GLP-1/Glucagon). The most advanced weight management peptide in clinical research — 24% body weight reduction in Phase 2 trials, outperforming all previous generations.

Purity

≥98% (HPLC verified)

Dosage

0.5mg → 4mg/week titration

Key Benefits

Triple receptor agonist
24% weight loss in trials
Increases metabolic rate
Superior to dual agonists

In Stock

₹7,000

≈ $82 USD

Research Use Only. This product is intended solely for in-vitro research. Not for human or animal consumption. Not approved by the FDA.